Immuron Receives AUD $306,154 R&D Tax Concession Refund

MELBOURNE, Australia, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (IMCIMRN, an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that under the Australian Government's Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD $306,154 for eligible research and development expenditure incurred during the 2021 Financial Year.

This release has been authorized by the directors of Immuron Limited.

COMPANY CONTACT:



Dr Jerry Kanellos, Ph.D.

Chief Executive Officer

Ph: +61 (0)3 9824 5254

info@immuron.com

US INVESTOR CONTACT



Dave Gentry, CEO

RedChip Companies Inc.

+1-407-491-4498

dave@redchip.com
 

About Immuron

Immuron Limited (IMCIMRN, is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

For more information visit: http://www.immuron.com



Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Health CarePress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!